News Roundup | India: DGHS Chops Ivermectin Nationally — How will ICMR & AIMS Weigh In?

Join the Conversation! | https://trialsitenews.com/
Article 1 | DGHS Hatchet Chops Ivermectin Nationally While Positioning Unproven Tocilizumab Despite Success of Uttar Pradesh—How will ICMR & AIMS Weigh In?
In India it appears that as quickly as select national health authorities included ivermectin in the national guidelines, so too, has the recommendation just as been rescinded despite what appears to be tremendous success in states such as Uttar Pradesh.

Article Link | https://trialsitenews.com/dghs-hatchet-chops-ivermectin-nationally-while-positioning-unproven-tocilizumab-despite-success-of-uttar-pradesh-how-will-icmr-aims-weigh-in/

Article 2 | After $356M in Federal Funds in Dec, Merck Secures $1.2B Federal Commitment to Buy its Experimental Drug Upon Key Milestones
In an interesting case that has some suggesting brilliant corporate enterprising business prowess while critics suggest it is an example of crony capitalism on display… Merck has recently announced it secured a $1.2 billion public commitment for up to $1.7 million courses of its still experimental antiviral drug Molnupiravir to the United States government.

Article Link | https://trialsitenews.com/after-356m-in-federal-funds-in-dec-merck-secures-1-2b-federal-commitment-to-buy-its-experimental-drug-upon-key-milestones/